Review article: Molecular, pathological and therapeutic features of human enteric neuropathies

Alimentary Pharmacology and Therapeutics

Volumn 28, Issue 1, 2008, Pages 25-42

  Di Nardo, G ^b   Blandizzi, C ^c   Volta, U ^d   Colucci, R ^c   Stanghellini, V ^d   Barbara, G ^d   Del Tacca, M ^c   Tonini, M ^e   Corinaldesi, R ^d   De Giorgio, R ^a,d  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIEMETIC AGENT; BENZAMIDE DERIVATIVE; BOTULINUM TOXIN; BUTYROPHENONE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CIPROFLOXACIN; CISAPRIDE; DOMPERIDONE; DOXYCYCLINE; ERYTHROMYCIN; GLYCERYL TRINITRATE; IMMUNOSUPPRESSIVE AGENT; ISOSORBIDE DINITRATE; LUBIPROSTONE; MACROLIDE; METOCLOPRAMIDE; METRONIDAZOLE; NEUROTROPHIN; NIFEDIPINE; OCTREOTIDE; PHOSPHODIESTERASE V INHIBITOR; PROKINETIC AGENT; PRUCALOPRIDE; RIFAXIMIN; SILDENAFIL; SOMATOSTATIN DERIVATIVE; TEGASEROD; UNINDEXED DRUG;

AUTOSOMAL INHERITANCE; BACTERIAL OVERGROWTH; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; ENTEROPATHY; ESOPHAGUS ACHALASIA; GASTROINTESTINAL MOTILITY DISORDER; GENE MUTATION; GENETIC PREDISPOSITION; HEADACHE; HEART ARRHYTHMIA; HIRSCHSPRUNG DISEASE; HUMAN; HYPERTROPHIC PYLORUS STENOSIS; HYPOTENSION; INCIDENCE; INTESTINE FUNCTION; INTESTINE INFECTION; INTESTINE INNERVATION; INTESTINE PSEUDOOBSTRUCTION; LOW DRUG DOSE; MYOTOMY; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROPATHY; PERIPHERAL EDEMA; PRIORITY JOURNAL; REVIEW; SLOW TRANSIT CONSTIPATION; STOMACH PARESIS; UNSPECIFIED SIDE EFFECT;

AUTONOMIC NERVOUS SYSTEM DISEASES; CONSTIPATION; ENTERIC NERVOUS SYSTEM; ESOPHAGEAL ACHALASIA; FEMALE; GASTROINTESTINAL MOTILITY; GASTROPARESIS; HIRSCHSPRUNG DISEASE; HUMANS; INTESTINAL PSEUDO-OBSTRUCTION;

EID: 44649102599     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03707.x     Document Type: Review

References (153)

1. Furness JB. The Enteric Nervous System. Oxford : Blackwell Publishing Ltd., 2006.
2. Wood JD. Intrinsic neural control of intestinal motility. Annu Rev Physiol 1981 43 : 33 51.
3. Wood JD. Neural and humoral regulation of gastrointestinal motility. In : Schuster MM, Crowell MD, Koch KL, eds. Gastrointestinal Motility in Health and Disease. London : BC Decker, 2002 : 19 42.
4. Collins SM. The immunomodulation of enteric neuromuscular function: implications for motility and inflammatory disorders. Gastroenterology 1996 111 : 1683 9.
5. Goyal RK, Hirano I. The enteric nervous system. New Engl J Med 1996 25 : 1106 15.
6. De Giorgio R, Camilleri M. Human enteric neuropathies: morphology and molecular pathology. Neurogastroenterol Motil 2004 16 : 515 31.
7. Coulie B, Camilleri M. Intestinal pseudo-obstruction. Annu Rev Med 1999 50 : 37 55.
8. Di Lorenzo C. Pseudo-obstruction: current approaches. Gastroenterology 1999 116 : 980 7.
9. Sanders KM, Koh SD, Ward SM. Interstitial cells of Cajal as pacemakers in the gastrointestinal tract. Annu Rev Physiol 2006 68 : 307 43.
10. Sarna SK. Are interstitial cells of Cajal plurifunction cells in the gut? Am J Physiol 2007 294 : G372 90.
11. Bassotti G, Villanacci V, Fisogni S, et al. Enteric glial cells and their role in gastrointestinal motor abnormalities: introducing the neuro-gliopathies. World J Gastroenterol 2007 13 : 4035 41.
12. Savidge TC, Sofroniew MV, Neunlist M. Starring roles for astroglia in barrier pathologies of gut and brain. Lab Invest 2007 87 : 731 6.
13. Park W, Vaezi MF. Etiology and pathogenesis of achalasia: the current understanding. Am J Gastroenterol 2005 100 : 1404 14.
14. Gershon MD, Kirchgessner AL, Wade PR. Functional anatomy of the enteric nervous system. In : Johnson LR, ed. Physiology of the Gastrointestinal Tract, 3rd edn, Chapter 9. New York : Raven Press, 1994 : 381 422.
15. De Giorgio R, Di Simone M, Stanghellini V, et al. Esophageal and gastric nitric oxide synthesizing innervation in primary achalasia. Am J Gastroenterol 1999 94 : 2357 62.
16. Holloway RH, Dodds WJ, Helm JF, Hogan WJ, Dent J, Arndorfer RC. Integrity of cholinergic innervation to the lower esophageal sphincter in achalasia. Gastroenterology 1986 90 : 924 9.
17. De Giorgio R, Guerrini S, Barbara G, Cremon C, Stanghellini V, Corinaldesi R. New insights into human enteric neuropathies. Neurogastroenterol Motil 2004 16 (Suppl. 1 143 7.
18. Kraichely RE, Farrugia G. Achalasia: physiology and etiopathogenesis. Dis Esophagus 2006 19 : 213 23.
19. Latiano A, De Giorgio R, Volta U, et al. HLA and enteric antineuronal antibodies in patients with achalasia. Neurogastroenterol Motil 2006 18 : 520 5.
20. Goldblum JR, Whyte RI, Orringer MB, Appelman HD. Achalasia. A morphologic study of 42 resected specimens. Am J Surg Pathol 1994 18 : 327 37.
21. Goldblum JR, Rice TW, Richter JE. Histopathologic features in esophagomyotomy specimens from patients with achalasia. Gastroenterology 1996 111 : 648 54.
22. Clark SB, Rice TW, Tubbs RR, Richter JE, Goldblum JR. The nature of the myenteric infiltrate in achalasia: an immunohistochemical analysis. Am J Surg Pathol 2000 24 : 1153 8.
23. Raymond L, Lach B, Shamji FM. Inflammatory aetiology of primary oesophageal achalasia: an immunohistochemical and ultrastructural study of Auerbach's plexus. Histopathology 1999 35 : 445 53.
24. Robertson CS, Martin BA, Atkinson M. Varicella-zoster virus DNA in the oesophageal myenteric plexus in achalasia. Gut 1993 34 : 299 302.
25. Birgisson S, Galinski MS, Goldblum JR, Rice TW, Richter JE. Achalasia is not associated with measles or known herpes and human papilloma viruses. Dig Dis Sci 1997 42 : 300 6.
26. Castagliuolo I, Brun P, Costantini M, et al. Esophageal achalasia: is the herpes simplex virus really innocent? J Gastrointest Surg 2004 8 : 24 30.
27. Verne GN, Sallustio JE, Eaker EY. Anti-myenteric neuronal antibodies in patients with achalasia. A prospective study. Dig Dis Sci 1997 42 : 307 13.
28. Eaker EY. Antimyenteric neuronal antibodies and motility. Gastroenterology 1998 114 : 421 2.
29. Moses PL, Ellis LM, Anees MR, et al. Antineuronal antibodies in idiopathic achalasia and gastro-oesophageal reflux disease. Gut 2003 52 : 629 36.
30. Bruley des Varannes S, Chevalier J, Pimont S, et al. Serum from achalasia patients alters neurochemical coding in the myenteric plexus and nitric oxide mediated motor response in normal human fundus. Gut 2006 55 : 319 26.
31. Stein DT, Knauer CM. Achalasia in monozygotic twins. Dig Dis Sci 1982 27 : 636 40.
32. Tullio-Pelet A, Salomon R, Hadj-Rabia S, et al. Mutant WD-repeat protein in triple-A syndrome. Nat Genet 2000 26 : 332 5.
33. Di Nardo G, Tullio-Pelet A, Annese V, et al. Idiopathic achalasia is not allelic to alacrima achalasia adrenal insufficiency syndrome at the ALADIN locus. Dig Liver Dis 2005 37 : 312 5.
34. Horowitz M, Fraser RJ. Gastroparesis: diagnosis and management. Scand J Gastroenterol 1995 213 (Suppl. 7 16.
35. Patrick A, Epstein O. Review article: gastroparesis. Aliment Pharmacol Ther 2008 27 : 724 40.
36. You CH, Chey WY, Lee KY, Menguy R, Bortoff A. Gastric and small intestinal myoelectric dysrhythmia associated with chronic intractable nausea and vomiting. Ann Int Med 1981 95 : 449 51.
37. Shellito PC, Warshaw AL. Idiopathic intermittent gastroparesis and its surgical alleviation. Am J Surg 1984 148 : 408 12.
38. Zarate N, Mearin F, Wang XY, Hewlett B, Huizinga JD, Malagelada JR. Severe idiopathic gastroparesis due to neuronal and interstitial cells of Cajal degeneration: pathological findings and management. Gut 2003 52 : 966 70.
39. Chinn JS, Schuffler MD. Paraneoplastic visceral neuropathy as a cause of severe gastrointestinal motor dysfunction. Gastroenterology 1988 95 : 1279 86.
40. De Giorgio R, Barbara G, Stanghellini V, et al. Idiopathic myenteric ganglionitis underlying intractable vomiting in a young adult. Eur J Gastroenterol Hepatol 2000 12 : 613 6.
41. Vanderwinden J-M, Mailleux P, Schiffmann SN, Vanderhaegen J-J, De Laet M-H. Nitric oxide synthase activity in infantile hypertrophic pyloric stenosis. New Engl J Med 1992 327 : 511 5.
42. Mashimo H, Kjellin A, Goyal RK. Gastric stasis in neuronal nitric oxide synthase-deficient knockout mice. Gastroenterology 2000 119 : 766 73.
43. Stanghellini V, Cogliandro RF, De Giorgio R, Barbara G, Salvioli B, Corinaldesi R. Chronic intestinal pseudo-obstruction: manifestations, natural history and management. Neurogastroenterol Motil 2007 19 : 440 52.
44. De Giorgio R, Sarnelli G, Corinaldesi R, Stanghellini V. Advance in our understanding of the pathology of chronic intestinal pseudo-obstruction. Gut 2004 53 : 1549 52.
45. Schuffler MD, Baird HW, Fleming CR, et al. Intestinal pseudo-obstruction as the presenting manifestation of small-cell carcinoma of the lung. A paraneoplastic neuropathy of the gastrointestinal tract. Ann Intern Med 1983 98 : 129 34.
46. Krishnamurthy S, Schuffler MD. Pathology of neuromuscular disorders of the small intestine and colon. Gastroenterology 1987 93 : 610 39.
47. Hall KE, Wiley JW. Neural injury, repair and adaptation in the GI tract. I. New insights into neuronal injury: a cautionary tale. Am J Physiol 1998 274 : G978 83.
48. De Giorgio R, Seri M, Cogliandro R, et al. Analysis of candidate genes for intrinsic neuropathy in a family with chronic idiopathic intestinal pseudo-obstruction. Clin Genet 2001 59 : 131 3.
49. Deglincerti A, De Giorgio R, Cefle K, et al. A novel locus for syndromic chronic idiopathic intestinal pseudo-obstruction maps to chromosome 8q23-q24. Eur J Hum Genet 2007 15 : 889 97.
50. Gargiulo A, Auricchio R, Barone MV, et al. Filamin A is mutated in X-linked chronic idiopathic intestinal pseudo-obstruction with central nervous system involvement. Am J Hum Genet 2007 80 : 751 8.
51. Finsterer J. Mitochondriopathies. Eur J Neurol 2004 11 : 163 86.
52. Hirano M, Silvestri G, Blake D, et al. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): clinical, biochemical, and genetic features of an autosomal recessive mitochondrial disorder. Neurology 1994 44 : 721 7.
53. Nishino I, Spinazzola A, Papadimitriou A, et al. Mitochondrial neurogastrointestinal encephalopathy: an autosomal recessive disorder due to thymidine phosphorylase mutations. Ann Neurol 2000 47 : 792 800.
54. Gillis L, Kaye E. Diagnosis and management of mitochondrial diseases. Pediatr Clin North Am 2002 49 : 203 19.
55. Martì R, Spinazzola A, Tadesse S, Nishino I, Nishigaki Y, Hirano M. Definitive diagnosis of mitochondrial neurogastrointestinal encephalomyopathy by biochemical assays. Clin Chem 2004 50 : 120 4.
56. Spinazzola A, Martí R, Nishino I, et al. Altered thymidine metabolism due to defects of thymidine phosphorylase. J Biol Chem 2002 277 : 4128 33.
57. Valentino ML, Martí R, Tadesse S, et al. Thymidine and deoxyuridine accumulate in tissues of patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). FEBS Lett 2007 581 : 3410 4.
58. Nishigaki Y, Marti R, Hirano M. ND5 is a hot-spot for multiple atypical mitochondrial DNA deletions in mitochondrial neurogastrointestinal encephalomyopathy. Hum Mol Genet 2004 13 : 91 101.
59. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is a inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990 348 : 334 6.
60. De Giorgio R, Barbara G, Stanghellini V, et al. Reduced Bcl-2 expression in the enteric nervous system as a marker for neuronal degeneration in patients with gastrointestinal motor disorders. Gastroenterology 2000 118 : A867.
61. Sarnelli G, Stanghellini V, Barbara G, et al. Reduced Bcl-2 expression and increased myenteric neuron apoptosis in patients with idiopathic enteric neuropathy. Gastroenterology 2005 128 : A23.
62. De Giorgio R, Guerrini S, Barbara G, et al. Inflammatory neuropathies of the enteric nervous system. Gastroenterology 2004 126 : 1872 83.
63. Smith VV, Gregson N, Foggensteiner L, Neale G, Milla PJ. Acquired intestinal aganglionosis and circulating autoantibodies without neoplasia or other neural involvement. Gastroenterology 1997 112 : 1366 71.
64. De Giorgio R, Barbara G, Stanghellini V, et al. Clinical and morphofunctional features of idiopathic myenteric ganglionitis underlying severe intestinal motor dysfunction: a study of three cases. Am J Gastroenterol 2002 97 : 2454 9.
65. Schäppi MG, Smith VV, Milla PJ, Lindley KJ. Eosinophilic myenteric ganglionitis is associated with functional intestinal obstruction. Gut 2003 52 : 752 5.
66. Accarino A, Colucci R, Barbara G, et al. Mast cell neuromuscular involvement in patients with severe gastrointestinal motility disorders. Gut 2007 39 (Suppl. 1 A18.
67. Lennon VA, Sas DF, Busk MF, et al. Enteric neuronal autoantibodies in pseudoobstruction with small-cell lung carcinoma. Gastroenterology 1991 100 : 137 42.
68. King PH, Redden D, Palmgren JS, Nabors LB, Lennon VA. Hu antigen specificities of ANNA-I autoantibodies in paraneoplastic neurological disease. J Autoimmun 1999 13 : 435 43.
69. Lennon VA. Calcium channel and related paraneoplastic disease autoantibodies. In : Peter JB, Shoenfeld Y, eds. Textbook of Autoantibodies. Amsterdam : Elsevier Science, 1996 : 139 47.
70. Wood JD. Neuropathophysiology of functional gastrointestinal disorders. World J Gastroenterol 2007 13 : 1313 32.
71. Sutton I, Winer JB. The immunopathogenesis of paraneoplastic neurological syndromes. Clin Sci (Lond) 2002 102 : 475 86.
72. Darnell RB, Posner JB. Paraneoplastic syndromes affecting the nervous system. Semin Oncol 2006 33 : 270 98.
73. Okano HJ, Darnell RB. A hierarchy of Hu RNA binding proteins in developing and adult neurons. J Neurosci 1997 17 : 3024 37.
74. Wakamatsu Y, Weston JA. Sequential expression and role of Hu RNA-binding proteins during neurogenesis. Development 1997 124 : 3449 60.
75. Lin Z, Gao N, Hu HZ, et al. Immunoreactivity of Hu proteins facilitates identification of myenteric neurones in guinea-pig small intestine. Neurogastroenterol Motil 2002 14 : 197 204.
76. De Giorgio R, Bovara M, Barbara G, et al. Anti-HuD-induced neuronal apoptosis underlying paraneoplastic gut dysmotility. Gastroenterology 2003 125 : 70 9.
77. Caras SD, McCallum HR, Brashear HR, Smith TK. The effect of human antineuronal antibodies on the ascending excitatory reflex and peristalsis in isolated guinea pig ileum: is the paraneoplastic syndrome a motor neuron disorder? Gastroenterology 1996 110 : A643.
78. Talamonti L, Li Q, Beyak M, et al. Sensory.motor abnormalities in severe gut dysmotility: role of anti-HuD neuronal antibodies. Neurogastroenterol Motil 2006 18 : 669.
79. De Giorgio R, Stanghellini V, Barbara G, et al. Primary enteric neuropathies underlying gastrointestinal motor dysfunction. Scand J Gastroenterol 2000 35 : 114 22.
80. Bassotti G, Villanacci V. Slow transit constipation: a functional disorder becomes an enteric neuropathy. World J Gastroenterol 2006 12 : 4609 13.
81. Kamm MA, Hawley PR, Lennard-Jones JE. Outcome of colectomy for severe idiopathic constipation. Gut 1988 29 : 969 73.
82. Bassotti G, Imbimbo BP, Betti C, Dozzini G, Morelli A. Impaired colonic motor response to eating in patients with slow-transit constipation. Am J Gastroenterol 1992 87 : 504 8.
83. Redmond JM, Smith GW, Barofsky I, Ratych RE, Goldsborough DC, Schuster MM. Physiological tests to predict long-term outcome of total abdominal colectomy for intractable constipation. Am J Gastroenterol 1995 90 : 748 53.
84. Villanacci V, Bassotti G, Cathomas G, et al. Is pseudomelanosis coli a marker of colonic neuropathy in severely constipated patients? Histopathology 2006 49 : 132 7.
85. Smith B. Myenteric plexus in Hirschprung's disease. Gut 1967 8 : 308 12.
86. Krishnamurthy S, Schuffler MD, Rohrmann CA, Pope CE. Severe idiopathic constipation is associated with a distinctive abnormality of the colonic myenteric plexus. Gastroenterology 1985 88 : 26 34.
87. Zenilman ME, Dunnegan DL, Soper NJ, Becker JM. Successful surgical treatment of idiopathic colonic dysmotility. The role of preoperative evaluation of coloanal motor function. Arch Surg 1989 124 : 947 51.
88. Porter AJ, Wattchow DA, Hunter A, Costa M. Abnormalities of nerve fibers in the circular muscle of patients with slow transit constipation. Int J Colorectal Dis 1998 13 : 208 16.
89. Faussone-Pellegrini MS, Infantino A, Matini P, Masin A, Mayer B, Lise M. Neuronal anomalies and normal muscle morphology at the hypomotile ileocecocolonic region of patients affected by idiopathic chronic constipation. Histol Histopathol 1999 14 : 1119 34.
90. Wedel T, Roblick UJ, Ott V, et al. Oligoneuronal hypoganglionosis in patients with idiopathic slow-transit constipation. Dis Colon Rectum 2002 45 : 54 62.
91. He CL, Burgart L, Wang L, et al. Decreased interstitial cell of Cajal volume in patients with slow-transit constipation. Gastroenterology 2000 118 : 14 21.
92. Lyford GL, He CL, Soffer E, et al. Pan-colonic decrease in interstitial cells of Cajal in patients with slow transit constipation. Gut 2002 51 : 496 501.
93. Wedel T, Spiegler J, Soellner S, et al. Enteric nerves and interstitial cells of Cajal are altered in patients with slow-transit constipation and megacolon. Gastroenterology 2002 123 : 1459 67.
94. Bassotti G, Villanacci V, Maurer CA, et al. The role of glial cells and apoptosis of enteric neurones in the neuropathology of intractable slow transit constipation. Gut 2006 55 : 41 6.
95. Bassotti G, Villanacci V, Cathomas G, et al. Enteric neuropathology of the terminal ileum in patients with intractable slow-transit constipation. Hum Pathol 2006 37 : 1252 8.
96. Koch TR, Carney JA, Go L, Go VL. Idiopathic chronic constipation is associated with decreased colonic vasoactive intestinal peptide. Gastroenterology 1988 94 : 300 10.
97. Lincoln J, Crowe R, Kamm MA, Burnstock G, Lennard-Jones JE. Serotonin and 5-hydroxyindolacetic acid are increased in the sigmoid colon in severe idiopathic constipation. Gastroenterology 1990 98 : 1219 25.
98. Tzavella K, Riepl RL, Klauser AG, Voderholzer WA, Schindlbeck NE, Muller-Lissner SA. Decreased substance P levels in rectal biopsies from patients with slow transit constipation. Eur J Gastroenterol Hepatol 1996 8 : 1207 11.
99. Sjolund K, Fasth S, Ekman R, et al. Neuropeptides in idiopathic chronic constipation (slow transit constipation). Neurogastroenterol Motil 1997 9 : 143 50.
100. Tomita R, Fujisaki S, Ikeda T, Fukuzawa M. Role of nitric oxide in the colon of patients with slow-transit constipation. Dis Colon Rectum 2002 45 : 593 600.
101. Kapur RP. Hirschprung disease and other enteric dysganglionoses. Crit Rev Clin Lab Sci 1999 36 : 225 73.
102. Heanue TA, Pachnis V. Enteric nervous system development and Hirschsprung's disease: advances in genetic and stem cell studies. Nat Rev Neurosci 2007 8 : 466 79.
103. Qualman SJ, Pysher T, Schauer G. Hirschprung disease: differential diagnosis and sequelae. Perspect Pediatr Pathol 1997 20 : 111 26.
104. Weinberg AG. Hirschprung's disease. A pathologist's view. Perspect Pediatr Pathol 1975 2 : 207 39.
105. Ballard ET. Ultrashort segment Hirschprung's disease: a case report. Pediatr Pathol Lab Med 1996 16 : 319 25.
106. Camilleri M. Enteric nervous system disorders: genetic and molecular insights for the neurogastroenterologist. Neurogastroenterol Motil 2001 13 : 277 95.
107. Robertson K, Mason I, Hall S. Hirschprung's disease: genetic mutations in mice and men. Gut 1997 41 : 436 41.
108. Martucciello G, Ceccherini I, Lerone M, Jasonni V. Pathogenesis of Hirschprung's disease. J Pediatr Surg 2000 35 : 1017 25.
109. Nagaya M, Kato J, Niimi N, Tanaka S, Wakamatsu N. Clinical features of a form of Hirschprung's disease caused by a novel genetic abnormality. J Pediatr Surg 2002 37 : 1117 22.
110. Eng C. RET proto-oncogene in the development of human cancer. J Clin Oncol 1999 17 : 380 93.
111. Romeo G, Ceccherini I, Celli J, et al. Association of multiple endocrine neoplasia type 2 and Hirschprung disease. J Intern Med 1998 243 : 515 20.
112. Hofstra RM, Wu Y, Stulp RP, et al. RET and GDNF gene scanning in Hirschprung patients using two dual denaturing gel systems. Hum Mutat 2000 15 : 418 29.
113. Doray B, Salomon R, Amiel J, et al. Mutation of the RET ligand, neurturin, supports multigenic inheritance in Hirschprung disease. Hum Mol Genet 1998 7 : 1449 52.
114. Pingault V, Bondurand N, Kuhlbrodt K, et al. SOX10 mutations in patients with Waardenburg-Hirschprung disease. Nat Genet 1998 18 : 171 3.
115. Pohl D, Tutuian R. Achalasia: an overview of diagnosis and treatment. J Gastrointestin Liver Dis 2007 16 : 297 303.
116. Annese V, Bassotti G. Non-surgical treatment of esophageal achalasia. World J Gastroenterol 2006 12 : 5763 6.
117. Bassotti G, Annese V. Review article: pharmacological options in achalasia. Aliment Pharmacol Ther 1999 13 : 1391 6.
118. Wen ZH, Gardener E, Wang YP. Nitrates for achalasia. Cochrane Database Syst Rev 2004 : CD002299.
119. Bortolotti M, Mari C, Lopilato C, Porrazzo G, Miglioli M. Effects of sildenafil on esophageal motility of patients with idiopathic achalasia. Gastroenterology 2000 118 : 253 7.
120. Vaezi MF, Richter JE. Current therapies for achalasia: comparison and efficacy. J Clin Gastroenterol 1998 27 : 21 35.
121. Cuilliere C, Ducrotte P, Zerbib F, et al. Achalasia: outcome of patients treated with intrasphincteric injection of botulinum toxin. Gut 1997 41 : 87 92.
122. Mikaeli J, Fazel A, Montazeri G, Yaghoobi M, Malekzadeh R. Randomized controlled trial comparing botulinum toxin injection to pneumatic dilatation for the treatment of achalasia. Aliment Pharmacol Ther 2001 15 : 1389 96.
123. Bansal R, Nostrant TT, Scheiman JM, et al. Intrasphincteric botulinum toxin versus pneumatic balloon dilatation for treatment of primary achalasia. J Clin Gastroenterol 2003 36 : 209 14.
124. Abir F, Modlin I, Kidd M, Bell R. Surgical treatment of achalasia: current status and controversies. Dig Surg 2004 21 : 165 76.
125. Haans JJ, Masclee AA. Review article: the diagnosis and management of gastroparesis. Aliment Pharmacol Ther 2007 26 (Suppl. 2 37 46.
126. Tonini M, De Ponti F, Di Nucci A, Crema F. Review article: cardiac adverse effects of gastrointestinal prokinetics. Aliment Pharmacol Ther 1999 13 : 1585 91.
127. Albibi R, McCallum RW. Metoclopramide: pharmacology and clinical application. Ann Intern Med 1983 98 : 86 95.
128. De Caestecker JS, Ewing DJ, Tothill P, Clarke BF, Heading RC. Evaluation of oral cisapride and metoclopramide in diabetic autonomic neuropathy: an eight-week double-blind crossover study. Aliment Pharmacol Ther 1989 3 : 69 81.
129. Jadcherla SR, Berseth CL. Effect of erythromycin on gastroduodenal contractile activity in developing neonates. J Pediatr Gastroenterol Nutr 2002 34 : 16 22.
130. Richards RD, Davenport K, McCallum RW. The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin. Am J Gastroenterol 1993 88 : 203.
131. Sturm A, Holtmann G, Goebell H, Gerken G. Prokinetics in patients with gastroparesis: a systematic analysis. Digestion 1999 60 : 422 7.
132. Miller LS, Szych GA, Kantor SB, et al. Treatment of idiopathic gastroparesis with injection of botulinum toxin into the pyloric sphincter muscle. Am J Gastroenterol 2002 97 : 1653 60.
133. Bromer MQ, Friedenberg F, Miller LS, Fisher RS, Swartz K, Parkman HP. Endoscopic pyloric injection of botulinum toxin A for the treatment of refractory gastroparesis. Gastrointest Endosc 2005 61 : 833 9.
134. Kim CH, Nelson DK. Venting percutaneous gastrostomy in the treatment of refractory idiopathic gastroparesis. Gastrointest Endosc 1998 47 : 67 70.
135. Fontana RJ, Barnett JL. Jejunostomy tube placement in refractory diabetic gastroparesis: a retrospective review. Am J Gastroenterol 1996 91 : 2174 8.
136. Zhang J, Chen JD. Systematic review: applications and future of gastric electrical stimulation. Aliment Pharmacol Ther 2006 24 : 991 1002.
137. Pironi L, Spinucci G, Paganelli F, et al. Italian guidelines for intestinal transplantation: potential candidates among the adult patients managed by a medical referral center for chronic intestinal failure. Transplant Proc 2004 36 : 659 61.
138. Barbara G, Stanghellini V, Brandi G, et al. Interactions between commensal bacteria and gut sensorymotor function in health and disease. Am J Gastroenterol 2005 100 : 2560 8.
139. Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med 1991 325 : 1461 7.
140. Emmanuel AV, Shand AG, Kamm MA. Erythromycin for the treatment of chronic intestinal pseudo-obstruction: description of six cases with a positive response. Aliment Pharmacol Ther 2004 19 : 687 94.
141. Camilleri M, Malagelada JR, Abell TL, Brown ML, Hench V, Zinsmeister AR. Effect of six weeks of treatment with cisapride in gastroparesis and intestinal pseudoobstruction. Gastroenterology 1989 96 : 704 12.
142. Di Lorenzo C, Reddy SN, Villanueva-Meyer J, Mena I, Martin S, Hyman PE. Cisapride in children with chronic intestinal pseudo-obstruction. An acute, double blind, crossover, placebo-controlled trial. Gastroenterology 1991 101 : 1564 70.
143. Abell TL, Camilleri M, DiMagno EP, Hench VS, Zinsmeister AR, Malagelada JR. Long-term efficacy of oral cisapride in symptomatic upper gut dysmotility. Dig Dis Sci 1991 36 : 616 20.
144. Camilleri M, Balm RK, Zinsmeister AR. Symptomatic improvement with one-year cisapride treatment in neuropathic chronic dysmotility. Aliment Pharmacol Ther 1996 10 : 403 9.
145. Stanghellini V, Cogliandro RF, De Giorgio R, et al. Natural history of chronic idiopathic intestinal pseudo-obstruction in adults: a single center study. Clin Gastroenterol Hepatol 2005 3 : 449 58.
146. Johanson J, Miner P, Parkman H, et al. Prucalopride improves bowel movement frequency and symptoms in patients with chronic constipation: results of two double blind, placebo-controlled trials. Gastroenterology 2000 118 : A175.
147. 4 receptor partial agonist, relieves key symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001 15 : 1655 66.
148. Wald A. Slow transit constipation. Curr Treat Options Gastroenterol 2002 5 : 279 83.
149. Rao SS. Constipation: evaluation and treatment. Gastroenterol Clin North Am 2003 32 : 659 83.
150. Pampati V, Fogel R. Treatment options for primary constipation. Curr Treat Options Gastroenterol 2004 7 : 225 33.
151. Coulie B, Szarka LA, Camilleri M, et al. Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans. Gastroenterology 2000 119 : 41 50.
152. Parkman H, Miner P, Rao SSC, et al. Neurotrophin-3 improves functional constipation. Am J Gastroenterol 2003 98 : 1338 47.
153. Winpenny JP. Lubiprostone. IDrugs 2005 8 : 416 22.